<s> Genetics Institute Inc. , Cambridge , Mass. , said it was awarded U.S. patents for Interleukin-3 and bone morphogenetic protein . </s>
<s> The patent for Interleukin-3 covers materials and methods used to make the human blood cell growth factor via recombinant DNA technology . </s>
<s> Sandoz Ltd. has licensed certain manufacturing and marketing rights for Interleukin-3 from Genetics Institute and is conducting preclinical studies with it . </s>
<s> Interleukin-3 may help in treating blood cell deficiencies associated with cancer treatment , bone marrow transplants and other blood-cell disorders , Genetics Institute said . </s>
<s> The second patent describes bone morphogenetic protein-1 , a substance that can induce formation of new cartilage . </s>
<s> The patent covers BMP-1 type proteins and pharmaceutical compositions and methods for treating bone or cartilage defects , Genetics Institute said . </s>
<s> The company added that it has filed patent applications `` on a large number of different BMP proteins '' and the patent on BMP-1 is the first it has received . </s>
<s> BMP products may be useful in fracture healing and in treating bone loss associated with periodontal disease and certain cancers , the company said . </s>
